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Background: Chronic inflammation-mediated β-cell apoptosis is known to decrease β-cell mass in diabetes leading to
reduced insulin secretion. Exposure to pro-inflammatory cytokines can stimulate apoptosis in pancreatic β-cells. The G
protein coupled receptor 40 (GPR40) is implicated for glucose induced insulin secretion. We hypothesized that GPR40
activation can protect β-cells from inflammation-induced apoptosis and restore glucose stimulated insulin secretion.
Results: By exposing NIT1 insulinoma cells and rat islets to a cocktail of pro-inflammatory cytokines (TNFα and IL1β), we
mimicked inflammatory signaling as seen by JNK and NFκB activation and increased mRNA levels of TNFα, IL1β and
NOS2a. These changes were reversed by pharmacological activation of GPR40 by a specific, small molecule, CNX-011-67.
Further, GPR40 activation reduced inflammation-mediated oxidative and endoplasmic reticulum (ER) stresses. Importantly,
GPR40 activation decreased inflammation-induced apoptosis as measured by key markers. These impacts of GPR40 were
mediated through activation of PLC, CaMKII, calcineurin and cAMP. Cell survival was also enhanced by GPR40 activation
as seen from the increased phosphorylation of Akt/PKB and enhanced expression of BCL2 and PDX1 genes. Interestingly,
GPR40 activation restored both, inflammation-mediated inhibition on insulin secretion and intracellular insulin content.
Conclusions: In this study, we provide evidences that CNX-011-67, a GPR40 agonist, reduces inflammatory signaling and
apoptosis in pancreatic β-cells while promoting insulin secretion and synthesis. Activation of GPR40 leads to attenuation
of β-cell dysfunction caused by chronic inflammation and thus could be of immense clinical value to improve insulin
secretion and β-cell survival.
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Reduction in absolute β-cell mass and/or function is linked
to type-1 and type-2 diabetes mellitus [1-3]. This decrease
in β-cell mass is primarily due to apoptosis driven by an in-
crease in cytokine levels and/or a nutrient overload [4,5]. In
fact, nutrient overload as represented by elevated levels of
saturated fatty acid and glucose increases cytokine produc-
tion from β-cells, activates JNK and NFκB signaling path-
ways [6], and triggers oxidative and ER stresses [7-11].
These conditions (nutrient overload) result in chronic low
grade inflammation [12-14] which play a central role in* Correspondence: m.r.jagannath@connexios.com
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unless otherwise stated.β-cell apoptosis [15]. Hence, it becomes imperative to de-
lineate impacts of this chronic low grade inflammation and
to make efforts overcome underlying severe consequences.
The β-cell mass is positively regulated by multiple
mechanisms [16] and mild hyperglycemia itself can yield a
compensatory increase in mass since glucose regulates β-
cell growth [17]. Insulin secreted from β-cells in response
to glucose activates Akt/PKB, a known inducer of cell
growth and survival through the IRS-PI3K pathway. Simi-
larly, IGF, insulin receptor, IRS2 and Akt have been associ-
ated with β-cell growth [18-23]. Thus, activation of insulin
signaling by stimulating its secretion can positively impact
β-cell survival and growth. For instance, GLP1 treatment,
which enhances insulin secretion, has a positive impact onLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
























Figure 1 CNX-011-67 is a specific agonist of GPR40. CNX-011-67
induced GPR40 activation was measured in GPR40 over-expressing CHOK1
cells by its potency to increase in cytoplasmic calcium level which was
abolished by PLC inhibitor (U73122) (n = 4, ***P < 0.001). CNX-011-67 did
not increase any cytoplasmic calcium level in cells not expressing GPR40.
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mediated by GLP1 has been shown to reduce inflamma-
tory signaling and apoptosis in β-cells [28-30].
The G-protein coupled receptor 40 (GPR40), also
known as free fatty acid receptor 1 (FFAR1) is highly
expressed in pancreatic β-cells. It is involved in fatty acid
mediated potentiation of insulin secretion. Activation of
GPR40 can increase insulin secretion [31-34] through
phopsholipase-C (PLC) -Ca+2 pathway only at stimulatory
glucose concentration.
Here, we propose that an increase in insulin secretion
mediated by GPR40 can activate Akt/PKB to positively
impact β-cell survival. Activation of GPR40 is also known
to improve calcium flux in β-cells under chronic inflam-
matory conditions [13]. Since calcium dynamics and
cAMP levels are coupled [35], we propose that GPR40 ac-
tivation also attenuates inflammatory signaling.
In this study, we activated GPR40 using a specific small
molecule agonist (CNX-011-67). Pharmacological activa-
tion of GPR40 by CNX-011-67 was very specific as an in-
crease in cytoplasmic calcium flux was seen only in cells
expressing GPR40 and no calcium flux was observed in
cells which did not express GPR40. Moreover, CNX-011-67
mediated calcium flux was mediated through PLC pathway.
Treatment of NIT1 cells and rat islets with CNX-011-67
showed a reduction in inflammatory signaling, inflamma-
tory cytokines gene expression, cellular oxidative and ER
stresses while increasing insulin secretion, intracellular in-
sulin content and pro-survival signaling pathways. Taken
together, GPR40 agonists provide a novel tool to counteract
inflammation mediated β-cell dysfunction.
Results
Pharmacological activation of GPR40 enhances
cytoplasmic calcium level in PLC dependent manner
GPR40 activation by small molecule agonist (CNX-011-67,
1 μM) significantly increased cytoplasmic calcium level
(9187 AFU versus (vs) 5967 AFU of control) only in
CHOK1 cells over-expressing mouse GPR40 compared to
the control (Figure 1). The cytoplasmic flux induced by
CNX-011-67 was PLC-dependent as treatment with a PLC
inhibitor (U73122) abolished this flux (5921 AFU vs 9187
AFU of CNX-011-67; Figure 1). Normal CHOK1 cells
which did not express GPR40 showed no increase in cyto-
plasmic calcium in response to CNX-011-67 (4813 AFU vs
4768 AFU of control, not significant). This data demon-
strates that CNX-011-67 specifically activates GPR40.
Activation of GPR40 attenuates cellular inflammation
Under chronic inflammatory conditions, NIT1 cells showed
a 4.4 fold increase in JNK phosphorylation (Figure 2A) and
60% decrease in IκB levels (Figure 2B) compare to un-
treated cells, indicative of increased NFκB signaling. Activa-
tion of GPR40 decreased inflammation-induced JNKphosphorylation (1.5 fold of control vs 4.4 fold with inflam-
mation) and increased IκB levels (1.3 fold of control vs 0.4
fold with inflammation) in NIT1 cells (Figure 2A and B).
Gene expression of both NF-κB (Figure 1C) and pro-
inflammatory cytokines such as IL1β (Figure 1D), TNFα
(Figure 1E), and NOS2a (Figure 1F) was up-regulated by
2.6, 4.3, 2.2 and 7.2 fold respectively under chronic in-
flammation in rat islets, consistent with increased JNK
and NF-κB activation. GPR40 activation reduced expres-
sion levels of NF-κB and pro-inflammatory genes to 1.5
(NF-κB), 2.5 (IL1β), 1.8 (TNFα) and 4.4 fold (NOS2a) re-
spectively. These results demonstrate that activation of
GPR40 can negate inflammatory signaling in β-cells.
GPR40 activation reduces cellular stress in β-cells
Since increased cellular stress is a major contributing factor
for β-cell apoptosis, we investigated whether GPR40 activa-
tion influences cellular stress (oxidative and ER stress).
Under conditions mimicking chronic inflammation, NIT1
cells showed 1.8 fold increase of ROS compared to control
which was brought back to normal upon GPR40 activation
(Figure 3A). Similarly, chronic inflammation induced
CHOP (DDIT3/GADD153) gene expression up to 1.6 fold
in rat islets which was brought back to 0.6 fold upon
GPR40 activation (Figure 3B). Like CHOP gene expression,
inflammation conditions increased BiP level (1.4 fold of
control) and eIF2α (1.2 fold of control) phosphorylation in
NIT1 cells (Figure 3C) which were reversed upon GPR40
activation (0.6 and 0.7 fold of control respectively) (Fig-
ure 3C). Taken together, these data demonstrate that activa-
tion of GPR40 significantly lowers inflammatory signaling
and cellular oxidative and ER stress.
GPR40 activation protects β-cells from
inflammation-induced apoptosis
To support the results from cellular oxidative and ER
stress, we next showed cellular apoptosis by different





Figure 2 GPR40 activation by CNX-011-67 reduces cellular inflammation. Western blot of NIT1 cells treated with inflammatory cytokines in
presence or absence of GPR40 agonist (A, B). Inflammatory cytokines (TNFα + IL1β) increased JNK phosphorylation (A) and reduced IκB level (B)
in NIT1 cells which were reversed by GPR40 activation. Total JNK and β-actin were used as loading control for normalization. Expression of NF-κB
(C), IL1β (D), TNFα (E) and NOS2a (F) genes were up-regulated under inflammatory conditions and were down-regulated by GPR40 activation in
rat islets. Gene expression was measured by qRT-PCR. (n = 4, **P < 0.01, ***P < 0.001).
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cant increase in number of condensed nuclei (Figure 4A, B).
Quantification data revealed that inflammation caused more
than two fold increase in these condensed nuclei (15.4%
apoptotic nuclei under inflammation compared to 6.6% in
control; Figure 4D). GPR40 activation under this condition
reduced nuclear fragmentation (Figure 4C) as number of
condensed nuclei was decreased (10.5% apoptotic nuclei;
Figure 4C, D). Chronic inflammation enhanced cytochrome-
c levels (Figure 4E) with a concomitant increase in Terminal
deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) positivity (Figure 4F). Similarly, caspase-3 activity
was also increased under chronic inflammation (163% of
control; Figure 4G). GPR40 activation significantly decreasedthese apoptotic effects of inflammation as cytochrome-c level
(Figure 4E), TUNEL positivity (Figure 4F) and caspase-3 ac-
tivity were reduced (98% of control; Figure 4G). The GPR40-
mediated inhibition of caspase-3 activity was PLC-dependent
since treatment with PLC inhibitor (U73122) attenuated the
effect of CNX-011-67 (Figure 4G). Interestingly, PLC inhib-
ition increased caspase-3 activity more than chronic inflam-
mation itself (Figure 4G). Thus, activation of GPR40 reduced
inflammation-induced apoptosis of β-cells.
GPR40 activation reduces apoptosis through CaMKII,
Calcineurin and cAMP signaling
In order to decipher how GPR40 activation rescued β-cell
apoptosis, we measured caspase-3 activity under chronic
AB
C
Figure 3 Chronic GPR40 activation reverses inflammation mediated increase in oxidative and ER stress. (A) NIT1 cells were treated for
72 h as indicated and ROS levels were measured by DCF fluorescence. ER stress was measured by expression of CHOP (DDIT3/GADD153) gene in
rat islets cultured under inflammation with or without GPR40 activator (B). (n = 4, **P < 0.01, ***P < 0.001). (C) NIT1 cells were treated as indicated
and total cell lysates were used for western blotting against BiP (GRP78/HSPA5) and p-eIF2a to study ER stress. β-actin and total eIF2a were used
as loading control for normalization.
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to dissect out the underlying molecular mechanism. Since
an increase in cytoplasmic calcium level activates CaMKII
and calcineurin, we inhibited their activity using AIP and
cyclosporine-A respectively [36,37] and measured changes
in GPR40 mediated caspase-3 activity. Activation of
GPR40 reduced inflammation-induced caspase-3 activity
(174% of control under inflammation vs 120% under
CNX-011-67) and this reduction was abolished by theinhibition of either CaMKII (237% of control) or calcine-
urin (246% of control) (Figure 5A). These data indicate an
important role for GPR40-induced calcium flux in decreas-
ing apoptosis. Interestingly, inhibition of either CaMKII or
calcineurin increased caspase-3 activity significantly more
than chronic inflammation alone (Figure 5A).
Increase in cytosolic calcium activates calcium-induced
adenylate cyclase in pancreatic β-cells thereby increasing
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Figure 4 Chronic GPR40 activation reverses inflammation mediated increase in apoptosis. Apoptotic cells were visualized as condensed
nuclei by propidium iodide fluorescence after chronic treatment of NIT1 cells with inflammatory cytokines in presence or ansence of GPR40
agonist (A-D). Representative pictures showing condensed nuclei with white arrow (A-C) demonstrating an increased number of apoptotic cells
under inflammation and reversal in apoptotic cells number by GPR40 activation. Thirty images having more than 800 total numbers of nuclei
were counted and quantification data were represented by bar graph (D). Inflammation conditions increased and GPR40 agonist decreased
cytochrome-c level in rat islets as measured using ELISA assay (E). In NIT1 cells, chronic inflammation increased and GPR40 agonist decreased
TUNEL positivity (F). Similarly, inflammation increased caspase-3 activity (G) in NIT1 cells which was reduced by GPR40 agonist. Caspase-3 activity
was measured by its ability to cleave DEVD substrate and release of fluorescence. GPR40 induced inhibition of caspae-3 activity was abolished by
incubating cells with PLC inhibitor (U73122). (n = 4, *P < 0.05, **P < 0.01, ***P < 0.001).
Verma et al. BMC Cell Biology 2014, 15:24 Page 5 of 12
http://www.biomedcentral.com/1471-2121/15/24activation increased cAMP in β-cells, which may help in-
hibit apoptosis. Under stimulatory glucose concentrations
in β-cells, we found that cAMP levels were increased
(0.94picomoles/mg protein at high glucose vs 0.30pico-
moles/mg protein at low glucose) (Figure 5B). Under
chronic inflammatory conditions, cAMP levels were signifi-
cantly reduced even in the presence of stimulatory glucose
concentrations (0.56picomoles/mg protein). This effect was
restored by GPR40 activation (cAMP levels: 1.45picomoles/
mg protein) (Figure 5B). To demonstrate the role of
GPR40-induced cAMP on apoptosis, we inhibited a soluble
isoform of ADCY with ADCY inhibitor (KH7) [38]. Similar
to the data obtained after CaMKII and calcineurin inhib-
ition, treatment with KH7 abolished the impact of GPR40
on caspase-3 activity (354% of control with KH7 vs 120%
with CNX-011-67) (Figure 5A). Consistent with the results
seen upon PLC, CaMKII and calcineurin inhibition; ADCY
inhibitor increased caspase-3 activity in β-cells significantly
more than with inflammation alone (Figures 4F and 5A),
indicating their role for normal β-cell functions. To better
understand the role of cAMP on β-cell apoptosis, we acti-
vated ADCYs to increase cAMP levels using forskolin
under inflammatory conditions and measured its effect on
apoptosis. As seen in Figure 5A, forskolin significantly
reduced caspase-3 activity (40% of control vs 174% under
inflammation) indicating a key role of cAMP to inhibit β-
cells apoptosis. Taken together, our data demonstrate thatactivation of GPR40 reduces inflammation-dependent
apoptosis through a mechanism involving PLC, CaMKII,
calcineurin and cAMP.GPR40 activation enhances cell survival signaling
We next examined weather GPR40 activation led to cell
survival as yet another mechanism to counteract apoptosis.
Activation of Akt/PKB, a known cell survival/growth signal
[39], was reduced under chronic inflammatory conditions
compared to control conditions (0.54 fold of control).
GPR40 activation restored Akt/PKB phosphorylation
under inflammatory conditions (1.51 fold of control vs 0.54
fold under inflammation) (Figure 6A). Expression of the
anti-apoptotic gene BCL2, was decreased under chronic in-
flammatory conditions (0.89 fold of control). Activation of
GPR40 increased BCL2 expression under these conditions
(1.26 fold of control) (Figure 6B). Expression of CDKN1a/
p21, a cell cycle inhibitor, was also increased under inflam-
matory conditions (2.7 fold of control), which was reduced
by GPR40 activation (2.1 fold of control) (Figure 6C). Fur-
ther, Pdx1 expression, which is required for β-cell mainten-
ance, was reduced under inflammatory conditions (0.35
fold of control) and was increased upon GPR40 activation
(0.81 fold of control) (Figure 6D). Thus, these data demon-















































































- - + +
CNX-011-67 - - - +




















Figure 5 Activation of GPR40 reduces apoptosis through cAMP and calcium signaling. (A) NIT1 cells were cultured under inflammation
conditions with or without GPR40 agonist for 72 h in presence of CaMKII (AIP), Calcineurin (CsA) and soluble ADCY (KH7) inhibitors or cAMP activator
(Fsk) as indicated (A). GPR40 agonist and Fsk reduced inflammation induced caspase-3 activity. AIP, CysA and KH7 blocked GPR40 agonist’s ability to
reduced caspase-3 activity. (B) After chronic culture for 72 h, NIT1 cells were pre-treated with low glucose containing KRBH followed by treatment for
1 h with low or high glucose and cAMP levels in cells were determined by enzyme immunoassay. (n = 4, *P < 0.05, **P < 0.01, ***P < 0.001).
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To verify that GPR40 activation plays a role in decreasing
inflammation, we measured its impact on insulin secretion
as an indicator of overall β-cell function. We observed im-
paired glucose-stimulated insulin secretion under chronic
inflammatory conditions (0.07 ng/islet vs 0.22 ng/islet
under control), which was significantly improved by GPR40
activation (0.20 ng/islet) (Figure 7A). GPR40 activation also
led to an increase in insulin secretion from control islets
(Additional file 1). Further, GPR40 activation increased cel-
lular ATP (24nano-moles/mg protein), which is required
for insulin secretion and was decreased under chronic in-
flammation (15nano-moles/mg protein vs 36nano-moles/
mg protein under control condition) (Figure 7B). In keep-
ing with these observations, we subsequently assessed theimpact of GPR40 activation on insulin synthesis. Expression
of insulin gene was significantly reduced under chronic in-
flammatory conditions (0.92 fold of control) (Figure 7C).
Activation of GPR40 under these conditions increased insu-
lin gene expression (1.14 fold of control) (Figure 7C). Con-
sistent with the findings of insulin gene expression and
insulin secretion, intracellular insulin content was de-
creased under chronic inflammatory conditions (1.5 ng/islet
vs 2.4 ng/islet under control) and was restored by GPR40
activation (2.0 ng/islet) (Figure 7D).
Based on our findings, we provide a schematic represen-
tation of how GPR40 activation led to counteract inflam-
mation mediated deleterious effects on pancreatic β-cells
(Figure 8). Exposure to inflammatory cytokines led to acti-








































































Figure 6 GPR40 activation and β-cells survival. (A) Phosphorylated Akt levels were measured by western blotting of NIT1 cells cultured for
72 h as indicated. Total Akt levels were measured for normalization. Chronic inflammation down-regulated expression of bcl2 (B) and pdx1 (D)
whereas it up-regulated expression of cdkn1a (C) gene in rat islets. Activation of GPR40 partially reversed expression of these genes. Gene
expression was quantified by qRT-PCR. (n = 4, *P < 0.05, **P < 0.01, ***P < 0.001).
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back loop. NFκB and JNK activation lead to increase oxida-
tive and ER stress, cytochrome-c release from mitochondria
and Caspase-3 activation thereby causing apoptosis and re-
duction in insulin synthesis and secretion. Activation of
GPR40 augments cytoplasmic calcium and cAMP levels
which potentiate insulin synthesis and secretion thereby
autocrine cell survival signaling. Moreover, elevated cAMP
levels reduce activation of NFκB and JNK and hence block
inflammatory signaling (Figure 8).
Discussion
In this present study we showed that activation of GPR40
by a small molecule, CNX-011-67, rescued inflammation-
mediated apoptosis in pancreatic β-cells. We demonstrated
that chronic inflammation, which has been shown to se-
verely impact β-cells’ function and mass [14], caused an
augmentation in cellular oxidative and ER stress, expres-
sion of pro-inflammatory cytokines genes and apoptosis.
We found that all these impacts of chronic inflammation
were reversed by GPR40 activation. Also we have observed
no significant change in the expression of GPR40 under in-
flammation condition with or without the receptor activa-
tion (data not shown).Chronic inflammation has been a mechanism implicated
for β-cell apoptosis in both type-1 and type-2 diabetes
[4,40-42]. Hence, it is important to counteract inflammation-
mediated changes in β-cells in order to protect them from
apoptosis. Therefore, we evaluated the potential of GPR40
activation as a mechanism to neutralize inflammation medi-
ated consequences. We have activated GPR40 using a small
molecule agonist (CNX-011-67) which showed an increase
in calcium flux. CNX-011-67 is a specific GPR40 agonist as
it enhanced calcium flux only in cells expressing GPR40.
Moreover, inhibition of PLC reversed CNX-011-67 induced
calcium flux as GPR40 activation mediates its effect via PLC-
Ca2+ pathway [31].
Since, inflammatory cytokines exert their effects through
activation of JNK and NFκB, we have showed that treat-
ment with GPR40 agonist was able to reduce their activa-
tion. These findings were also supported by a decrease in
pro-inflammatory cytokines gene expression by GPR40
agonist. Activation of JNK and NFκB has been shown to
up-regulate these pro-inflammatory cytokines [43], hence
their reduced activation by GPR40 agonist led to a de-
creased expression of these genes (TNFα, IL1β, Nos2a).
Thus, GPR40 activation not only blocked impact of those
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Figure 7 GPR40 activation improves insulin synthesis and secretion. (A) After chronic culture for 72 h, rat islets were pre-treated with low
glucose containing KRBH followed by treatment for 2 h with low or high glucose. Amount of secreted insulin in buffer (A) and intracellular insulin
content (D) were measured using ELISA. Likewise, NIT1 cells were also cultured and treated followed by cellular ATP levels estimation using lucif-
erase based luminescence assay (B). Insulin gene transcripts (C) were measured in rat islets after chronic culture under indicated condition by
qRT-PCR. (n = 4, *P < 0.05, **P < 0.01, ***P < 0.001).
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chronic low grade inflammation maintenance.
Elevated cellular oxidative and ER stress under nutrient
overload condition can cause β-cells apoptosis [7-11]. In
fact, we also observed increased oxidative and ER stress
after pro-inflammatory cytokines treatment which was
abolished by GPR40 agonist. Under inflammatory condi-
tions, an increased level of β-cell death was observed as
measured by cytochrome-c release, TUNEL positivity,
Caspase-3 activation and nuclear fragmentation. In consist-
ent with above mentioned findings with GPR40 activation,
we observed diminished apoptosis in pancreatic β-cells
upon GPR40 agonist treatment.
In order to dissect the mechanism by which GPR40 acti-
vation reduced β-cells apoptosis, we used various pharma-
cological agents to inhibit or activate key intracellular
signaling pathways. As expected, inhibition of PLC signal-
ing by U73122 abolished GPR40 agonist impact on apop-
tosis because GPR40 exerts its effect by PLC activation.
Interestingly, PLC inhibition caused a higher increase in
Caspase-3 activity compared to inflammation alone, indi-
cating its importance for normal physiological functionsof β-cells. In fact, elevated glucose level can cause activa-
tion of PLC signaling in islets [44]. Activation of PLC leads
to ER calcium release; hence we next tested the role of cal-
cium signaling for GPR40 induced reduction in apoptosis.
Increase in cytoplasmic calcium can lead to activation of
calcium-calmodulin dependent protein kinase (CaMK)
and calcineurin-NFAT pathways. In order to specify which
of these pathways was involved in the ability of GPR40 to
counteract inflammation induced apoptosis, we inhibited
each of these and observed their effect. Inhibition of CaM-
KII, the major isoform present in β-cells, showed a pro-
nounced increase in caspase-3 activity. Similar results
were obtained after calcineurin inhibition. Interestingly,
inhibition of either CaMKII or calcineurin caused in-
creased caspase-3 activity higher than that achieved by in-
flammation itself, signifying their importance in normal
physiology of β-cells.
Increase in cytoplasmic calcium level is coupled with an
increase in cAMP level due to presence of calcium acti-
vated ADCY in β-cells. We tested the possibility that in-
crease in cytoplasmic calcium level by GPR40 activation











Insulin  synthesis 
Insulin secretion
cAMP
Figure 8 Schematic representation of mechanisms involved for
β-cells apoptosis caused by inflammatory cytokines exposure
and its reversal by GPR40 activation. Pointed arrows represent
activatory signals and blunted lines represent inhibitory signals. Signals
propagated from inflammatory cytokines are shown as normal arrows
while signals propagated from GPR40 activation are shown as
broken arrows/lines.
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mation condition and were restored by GPR40 agonist. To
demonstrate the importance of GPR40-induced cAMP
level for caspase-3 activity, we inhibited a soluble isoform
of ADCY present in β-cells which is known to mediate
cAMP oscillation [38,45]. Similar to data obtained with
PLC, CaMKII and calcineurin inhibitor; inhibition of
sADCY caused a drastic increase in caspase-3 activity at
levels higher than that achieved with inflammation alone.
Since these inhibitors are known to suppress insulin secre-
tion, their exposure might have reduced autocrine survival
‘insulin-PI3K-Akt’ signaling. In contrast, increase in cAMP
level by forskolin led to a significant reduction in caspase-
3 activity indicating an independent role of cAMP for re-
duction in β-cell death. Treatment with GLP1, which can
also increase cAMP levels, has been shown to reduce
apoptosis in pancreatic β-cells [28-30]. Thus, our data col-
lectively demonstrate that GPR40 activation relayed its
signal to multiple arms of intracellular signaling pathways
to reduce inflammation mediated apoptosis.
GPR40 activation not only inhibited β-cell apoptosis but
also activated cell survival pathways. Its activation led to
an increase in ATP level which together with elevated
Ca2+ and cAMP level caused a significant increase in
glucose-stimulated insulin secretion. This secreted insulin
can lead to Akt/PKB phosphorylation in an autocrine
manner. The level of phosphorylated Akt, a well knownmarker for cell survival and proliferation, was reduced
under chronic inflammation conditions, together with a
reduction in insulin secretion. GPR40 agonist reversed this
decrease in pAkt level. Similarly, BCL2 and PDX1 expres-
sion were reduced under inflammation and were restored
by GPR40 agonist. PDX1 maintains β-cell phenotype and
also regulates insulin synthesis. In consistent with PDX1
data, inflammation reduced insulin gene transcription and
intracellular insulin content and their levels were restored
by GPR40 agonist. Under this condition we did not ob-
serve any change in the glucagon expression in rat islets
(data not shown). This is consistence with the fact that
GPR40 expression in predominant only in β-cells.
We have earlier showed that activation of GPR40 by oral
administration of CNX-011-67 in male ZDF rats reduces
β-cells apoptosis, increases insulin and PDX1 positive cell
number and insulin secretion [46]. It should be noted that
ZDF rat is an animal model of diabetes having high
chronic systemic inflammation [47,48]. Hence, our in vitro
data are in agreement with in vivo findings. Taken to-
gether, our data demonstrate that GPR40 activation by
CNX-011-67 reduces inflammation induced apoptosis, en-
hances β-cell survival and improves β-cell function as
measured by insulin synthesis and secretion.
Conclusions
In this study, we demonstrated that activation of GPR40,
which is implicated for glucose induced insulin secretion,
can rescue pancreatic β-cells from inflammation induced
dysfunction. GPR40 activation increased cytoplasmic cal-
cium level in a PLC dependent manner. We also established
the molecular link of GPR40 activation and downstream
calcium flux to cellular cAMP levels. GPR40 mediated its
impact through CaMKII, NFAT and cAMP as their inhib-
ition totally reversed the protective impact on β-cells apop-
tosis. Moreover, GPR40 activation promoted β-cell survival
signaling which was impaired under chronic inflammatory
conditions. These survival signaling might have been initi-
ated by insulin as GPR40 activation led to enhanced insulin
secretion. This study provides basis for the development of
GPR40 activators that might be an effective therapeutic




Male Wistar rats (8–10 weeks, 180-240gm body weight;
Charles River Lab, USA) were used for islet isolation. All
experimental protocols have been approved by Institu-
tional Animal Ethics Committee (IAEC) of Connexios Life
Sciences, which is recognized by the Committee for the
Purpose of Control and Supervision on Experiments on
Animals (CPCSEA), India. Excess anesthesia was used to
kill the animals and the pancreata were cut into 1-2 mm
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collagenase-II (2 mg/ml in HBSS; Sigma) at 37°C for
20 min. The reaction was stopped by adding two volumes
of culture medium (RPMI containing 10%FBS; Invitrogen)
and gently triturated. The cell pellet was obtained after cen-
trifugation at 100Xg for 5 min and then washed resus-
pended in 4 ml of Histopaque (1.119 gm/ml; Sigma).
Histopaque (1.077 mg/ml; 3 ml) followed by culture
medium were overlaid on this suspension and density gra-
dient centrifugation was carried out. The islets were recov-
ered from the interface of culture medium and Histopaque
1.077 and then washed with HBSS. The purified islets were
then handpicked under a stereo-zoom microscope (Nikon,
Japan) and used for subsequent experiments.
Cell culture and treatment
NIT1 cell line (ATCC) was cultured under either control
or inflammation (TNFα + IL1β, both 10 ng/ml) conditions
for 72 h in presence or absence of GPR40 agonist (CNX-
011-67, 1 μM). For Caspase-3 assay, NIT1 cells were cul-
tured for 72 h in presence or absence of the following
pharmacological modulators- PLC inhibitor (U73122, 2 μM),
soluble adenylate cyclase (ADCY) inhibitor (KH7, 30 μM),
non-specific ADCY activator (forskolin, 10 μM), calcium-
calmodulin kinase-II (CaMKII) inhibitor (AIP, 1 μM) and
calcineurin inhibitor (Cyclosporin A: CysA, 1 μM). Treat-
ments for rat islets were the same as described for NIT1
cells above.
Calcium flux
CHOK1 cells over-expressing mouse GPR40 (Cytobox)
were plated in 96-black well plate. Cells were washed with
KRBH and loaded with Fluo-4-AM, a calcium indicator
fluorescent dye (Invitrogen), at 37°C for 1 h. Basal fluores-
cence readings were taken at 485 nm excitation and at
520 nm emission. Cells were then induced with GPR40
agonist (CNX-011-67, 1 μM) in presence or absence of
PLC inhibitor (U73122, 10 μM) followed by fluorescence
readings for induced calcium flux. Changes in fluores-
cence readings between basal and induced conditions in
different treatments were defined as arbitrary fluorescence
units (AFU). Normal CHOK1 cells not expressing GPR40
were used as a control for the experiment.
Western blotting
After incubation, NIT1 cells were lysed and total proteins
were resolved by SDS-PAGE followed by transfer to nitro-
cellulose membrane. After blocking with BSA, the mem-
brane was incubated overnight at 4°C with primary
antibody followed by washing and incubation with HRP-
conjugated secondary antibody. Primary antibodies used
are pAKT, AKT, pJNK, JNK, IkB and β-actin (Cell Signaling
Technology). The blot was developed using chemilumines-
cence substrate (Pierce) and exposed to X-ray film.Densitometric analyses were carried out using Image-J
(NIH) software.
RNA isolation, reverse transcription and quantitative real
time polymerase chain reaction (qPCR)
Total RNA was extracted from treated islets using Trizol
reagent (Sigma, St. Louis, MO, USA), and was used as a
template for cDNA synthesis with reverse transcriptase
and random hexamer primers (ABI, CA, USA). Quantifi-
cation of gene expression was done using SYBR Green
PCR Master Mix (Eurogenetic, Belgium) using the
ABI7500 fast thermal cycler. We examined expression for
those genes whose primers generated a single peak in the
melting curve analysis and a single, specific band in agar-
ose gel electrophoresis. Genes analyzed in this study were
NF-κB, IL1β, TNFα, NOS2a, CHOP, BCL2, CDKN1A,
PDX1 and Insulin. β-actin or 18S rRNA was used as a
housekeeping gene control. The primer sequences are
provided in the Additional file 2.
Caspase-3 assay
After 72 h of incubation, NIT1 cells were lysed in lysis
buffer followed by estimation of Caspase-3 activity.
Caspase-3 activity was measured by cleavage of its sub-
strate (Ac-DEVD-R110; Invitrogen) and release of fluores-
cent R110 which was measured at 485 nm excitation and
530 nm emission. Activity of caspase-3 (as nano-moles of
R110 released) was normalized to total cellular protein.
Change in Caspase-3 activity under different conditions
was represented as% of control.
Nuclear fragmentation assay
NIT1 cells were fixed after chronic treatments of inflam-
mation and GPR40 agonist. Nuclei were stained with pro-
pidium iodide (PI) and morphology of nuclei was studied
microscopically. Images were captured at 100X magnifica-
tion for analysis. For each set more than 800 nuclei were
counted and fragmented, shrunken or condensed nuclei
were taken to indicate apoptotic nuclei. Data were pre-
sented as% of apoptotic nuclei.
Cytochrome-c assay
Rat islets were treated under inflammation and GPR40
agonist. After treatment media was removed, islets were
washed three times with PBS, followed by solubilization
of the cell membrane using 1xPBS and 0.5% triton-X-
100. Cytochrome C levels were measured according to
the manufacturer’s instructions (RnD Biosystems).
TUNEL assay
After chronic treatment with inflammation and GPR40
agonist, NIT1 cells were washed with PBS and fixed with
1% paraformaldihyde. Fragmented DNA was labeled using
ApopTag® Peroxidase Apoptosis Detection Kit (Millipore)
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H2O2. TUNEL levels were normalized to total cellular
protein amount.
Insulin secretion and intra-cellular insulin content analysis
Following chronic treatment of inflammation and GPR40
agonist, size-matched islets were picked under a micro-
scope and transferred into 24-well plates containing 1 ml
KRBH buffer (2.5 mM glucose)/well and pre-incubated at
37°C/5% CO2 for 1 h. The buffer was then carefully re-
moved from the wells and the islets were induced in fresh
KRBH buffer (250 μl/well) containing low (2 mM) or high
glucose (11 mM) at 37°C/5% CO2 for 2 h. The supernatant
was removed from the islets and stored at −70°C for ELISA.
Secreted insulin was measured in the KRBH buffer using
ELISA (Mercodia) as per manufacturer’s instructions. Insu-
lin secretion was represented as the amount of insulin se-
creted (ng) per islet. Islet lysates were used to measure
intracellular insulin content, which was also represented as
the amount of insulin (ng) per islet.Measurement of ATP and cAMP level
NIT1 cells were cultured under inflammation and GPR40
agonist and then washed with KRBH buffer followed by
pre-incubation at 37°C/5% CO2 for 1 h in the same buffer.
Subsequently, cells were treated with low (2 mM) or high
glucose (11 mM) at 37°C/5% CO2 for 1 h followed by esti-
mation on cAMP or ATP in cell lysates. ATP determination
kit (Invitrogen) and Amersham cAMP Biotrak Enzymeim-
munoassay (EIA) System (GE Healthcare) were used for
the estimation of ATP and cAMP respectively.Measurement of cellular ROS level
After chronic treatments of inflammation and GPR40
agonist for 72 h, NIT1 cells were loaded for 1 h with
DCFH-DA dye for ROS measurement (Invitrogen). Cells
were lysed and lysates were transferred to 96-black well
plate to measure increase in DCF fluorescence at 485 nm
excitation and 528 nm emission. Amount of ROS was nor-
malized to total cellular DNA which was measured using
bis-benzamide fluorescence at 360 nm exication and
460 nm emission.Statistical analysis
Data are expressed as mean ± SEM and significance was
calculated using the unpaired Student’s t-test. *indicates
p < 0.05; **indicates p < 0.01; ***indicates p < 0.001 com-
pared to the respective control. Each data point consists
of four individual replicates and experiments were re-
peated to check reproducibility. Miscrosoft Excel was
used for statistical analysis.Additional files
Additional file 1: Impact of GPR40 agonist (CNX-011-67) on insulin
secretion from rat islets.
Additional file 2: List of primers used in the study.
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